Biocryst Pharmaceuticals (BCRX) Operating Leases (2020 - 2026)

Biocryst Pharmaceuticals has reported Operating Leases for 7 years, with the latest figure at $13.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 66.86% year-over-year to $13.0 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (up 66.86% YoY), and the FY2025 full-year result was $8.6 million, down 3.27% from the prior year.
• Operating Leases for Q1 2026 stood at $13.0 million, up from $8.6 million in the prior quarter.
• The five-year high for Operating Leases was $13.0 million in Q1 2026, with the low at $4.0 million in Q4 2022.
• Historically, Operating Leases has averaged $8.4 million across 5 years, with a median of $8.4 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Leases surged 134.62% — and 2024, when it plunged 34.15%.
• Biocryst Pharmaceuticals' Operating Leases stood at $4.0 million in 2022, then surged by 134.62% to $9.4 million in 2023, then retreated by 6.21% to $8.9 million in 2024, then decreased by 3.27% to $8.6 million in 2025, then soared by 51.44% to $13.0 million in 2026.
• The last three Operating Leases figures came in at $13.0 million (Q1 2026), $8.6 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.